Chao-Sheng Liao
Overview
Explore the profile of Chao-Sheng Liao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuo M, Chen H, Chen C, Fann J, Chen S, Chiu S, et al.
World J Gastroenterol
. 2016 Mar;
22(12):3460-70.
PMID: 27022228
Aim: To assess the cost-effectiveness of two population-based hepatocellular carcinoma (HCC) screening programs, two-stage biomarker-ultrasound method and mass screening using abdominal ultrasonography (AUS). Methods: In this study, we applied a...
2.
Chiu H, Chen S, Yen A, Chiu S, Fann J, Lee Y, et al.
Cancer
. 2015 May;
121(18):3221-9.
PMID: 25995082
Background: The effectiveness of fecal immunochemical testing (FIT) in reducing colorectal cancer (CRC) mortality has not yet been fully assessed in a large, population-based service screening program. Methods: A prospective...
3.
Young K, Bai C, Su H, Tsai P, Pu C, Liao C, et al.
Antiviral Res
. 2014 Aug;
110:158-67.
PMID: 25151487
More than 20% of chronic hepatitis C (CHC) patients receiving interferon-alpha (IFN-α)-based anti-hepatitis C virus (HCV) therapy experienced significant depression, which was relieved by treatment with fluoxetine. However, whether and...
4.
Lin C, Young K, Bai C, Yu B, Ma C, Chien Y, et al.
Biomed Res Int
. 2014 Apr;
2014:787924.
PMID: 24757676
Peroxisome proliferator-activated receptor gamma (PPARγ) agonist has anti-inflammatory and anticancer properties. However, the mechanisms by which PPARγ agonist rosiglitazone interferes with inflammation and cancer via phosphatase and tensin homolog-(PTEN)-dependent pathway...
5.
Yen A, Chen S, Chiu S, Fann J, Wang P, Lin S, et al.
Int J Cancer
. 2014 Feb;
135(5):1203-12.
PMID: 24482014
We sought to assess how much of the variation in incidence of colorectal neoplasia is explained by baseline fecal hemoglobin concentration (FHbC) and also to assess the additional predictive value...
6.
Liao C, Lin Y, Chang H, Chen Y, Chong L, Chen C, et al.
World J Gastroenterol
. 2013 Dec;
19(45):8366-72.
PMID: 24363529
Aim: To determine the role of the fecal immunochemical test (FIT), used to evaluate fecal hemoglobin concentration, in the prediction of histological grade and risk of colorectal tumors. Methods: We...
7.
Chang H, Lin Y, Yen A, Chen S, Wu W, Chiu S, et al.
Anticancer Res
. 2013 Nov;
33(11):5171-8.
PMID: 24222166
Aim: Locoregional treatment [including percutaneous ethanol injection (PEI) therapy and transcatheter arterial chemoembolization (TACE)] provides an alternative treatment for early-diagnosed hepatocellular carcinoma (HCC). However, the long-term survival of patients after...
8.
Chen L, Yen A, Fraser C, Chiu S, Fann J, Wang P, et al.
BMJ Open
. 2013 Nov;
3(11):e003740.
PMID: 24202058
Objective: To assess the effect of an incremental increase in faecal haemoglobin (f-Hb) concentration on colorectal cancer (CRC) mortality and all-cause death. Design: We conducted an observational study of cohorts...
9.
Lee Y, Chiu H, Chiang T, Yen A, Chiu S, Chen S, et al.
BMJ Open
. 2013 Nov;
3(10):e003989.
PMID: 24176798
Objective: Highly sensitive guaiac-based faecal occult blood (Hemoccult SENSA) and Helicobacter pylori stool antigen testing might help detect upper gastrointestinal lesions when appended to a colorectal cancer screening programme with...
10.
Lin C, Young K, Bai C, Yu B, Ma C, Chien Y, et al.
Immunopharmacol Immunotoxicol
. 2013 Sep;
35(6):669-77.
PMID: 24053326
Context: Metformin is widely used for treatment of type 2 diabetes and has a potential application on the treatment of inflammation and cancer. Phosphatase and tensin homolog (PTEN) plays a...